These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18972468)

  • 1. Small-molecule inhibitors of PDK1.
    Peifer C; Alessi DR
    ChemMedChem; 2008 Dec; 3(12):1810-38. PubMed ID: 18972468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
    Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
    Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
    Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
    J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
    Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
    Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells.
    Yang KJ; Piao L; Shin S; Shin SY; Li Y; Lee H; Tran Q; Park J; Hong S; Brazil DP; Hemmings BA; Kim SH; Park J
    Anticancer Res; 2017 Oct; 37(10):5415-5423. PubMed ID: 28982851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PDK1 in cancer.
    Raimondi C; Falasca M
    Curr Med Chem; 2011; 18(18):2763-9. PubMed ID: 21568903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.
    Arico S; Pattingre S; Bauvy C; Gane P; Barbat A; Codogno P; Ogier-Denis E
    J Biol Chem; 2002 Aug; 277(31):27613-21. PubMed ID: 12000750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
    Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. For a PDK1 inhibitor, the substrate matters.
    Knight ZA
    Biochem J; 2011 Jan; 433(2):e1-2. PubMed ID: 21175429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of high-throughput TR-FRET and AlphaScreen assays for identification of potent inhibitors of PDK1.
    Xu Z; Nagashima K; Sun D; Rush T; Northrup A; Andersen JN; Kariv I; Bobkova EV
    J Biomol Screen; 2009 Dec; 14(10):1257-62. PubMed ID: 19822882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
    Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
    Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
    Sestito S; Nesi G; Daniele S; Martelli A; Digiacomo M; Borghini A; Pietra D; Calderone V; Lapucci A; Falasca M; Parrella P; Notarangelo A; Breschi MC; Macchia M; Martini C; Rapposelli S
    Eur J Med Chem; 2015 Nov; 105():274-88. PubMed ID: 26498573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
    Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
    Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils.
    Sturm EM; Parzmair GP; Radnai B; Frei RB; Sturm GJ; Hammer A; Schuligoi R; Lippe IT; Heinemann A
    Eur J Immunol; 2015 May; 45(5):1548-59. PubMed ID: 25645675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
    Zhang J; Yang C; Zhou F; Chen X
    Oncol Rep; 2018 Jun; 39(6):2951-2959. PubMed ID: 29658600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis-induced effects of extract from Artemisia annua Linné by modulating PTEN/p53/PDK1/Akt/ signal pathways through PTEN/p53-independent manner in HCT116 colon cancer cells.
    Kim EJ; Kim GT; Kim BM; Lim EG; Kim SY; Kim YM
    BMC Complement Altern Med; 2017 Apr; 17(1):236. PubMed ID: 28454566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
    Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
    Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.